Nautilus Biotechnology to Announce Third Quarter 2024 Financial Results on October 29, 2024
Rhea-AI Summary
Nautilus Biotechnology (NASDAQ: NAUT), a pioneer in single molecule protein analysis platforms, has announced it will release its third quarter 2024 financial results on Tuesday, October 29, 2024, before the market opens. The company's management will host a conference call and webcast at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time on the same day to discuss the results, business developments, and future outlook.
Interested parties can access the live audio webcast of the conference call through the 'Investors' section of Nautilus Biotechnology's official website at www.nautilus.bio. This event provides an opportunity for stakeholders and investors to gain insights into the company's financial performance and strategic direction.
Positive
- None.
Negative
- None.
SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the third quarter 2024 before market open on Tuesday, October 29, 2024.
The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the “Investors” section of the company website at: www.nautilus.bio.
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.
Media Contact
press@nautilus.bio
Investor Contact
investorrelations@nautilus.bio